From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors?
From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors?
Created by
Presenter
Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis